LLY | Eli Lilly and Company Stock Overview

(Stock Exchange: NYSE)

Day's Range	735.46 - 757.37
52 Week Range	561.65 - 972.53
Beta	0.42
Implied Volatility	40.18%
IV Rank	46.16%
Day's Volume	4,459,249
Average Volume	3,356,271
Shares Outstanding	949,316,000
Market Cap	715,224,167,560
Sector	Healthcare
Industry	Drug Manufacturers - General
IPO Date	1972-06-01

Valuation
Profitability
Growth
Health
P/E Ratio	81.27
Forward P/E Ratio	55.84
EPS	9.27
1YR Price Target	600.00
Dividend Yield	0.71%
Dividend Per Share	5.37
Dividend ExDate	2023-08-14
Dividend PayDate	2023-09-08
Employees	43,000
Country	USA
Website	LLY

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

LLY's peers: ABBV, ABT, AMGN, AZN, BMY, GILD, JNJ, PFE, MRK, NVS, OGN, SCLX

*Chart delayed

Analyzing fundamentals for LLY we got that it has average fundamentals where Valuation is considered to be significantly overvalued, Profitability is stunning wealthy, Growth is very good and Health is weak. For more detailed analysis please see LLY Fundamentals page.

Watching at LLY technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on LLY Technicals page.